RCM
ALDR

Riverhead Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Riverhead Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,825
Closed -$30K – 1594
2018
Q3 		$30K Buy
1,825
+860
+89% +$15.5K ﹤0.01% 1522
2018
Q2 		$15K Buy
+965
New +$14.7K ﹤0.01% 1520

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Riverhead Capital Management's ALDR Position: Q4 2018 in Review

Riverhead Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 1,825 shares — an estimated $30K sold.

Riverhead Capital Management first reported a position in ALDR in Q2 2018 and held it in 2 quarters. The position peaked at $30K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

  • Riverhead Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 1,825 Alder Biopharmaceuticals shares in Q4 2018, an estimated $30K.
  • Riverhead Capital Management first reported a position in Alder Biopharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Riverhead Capital Management's Alder Biopharmaceuticals position peaked at $30K in Q3 2018.
  • 124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.